A ZDNET wearable test over one month compares three blood-pressure-capable smartwatches against a Garmin Index BP Monitor and finds Amazfit’s Cheetah 2 Ultra/Balance 3 readings were usually within ~2–4 mmHg systolic and diastolic accuracy, while Samsung Galaxy Watch Ultra tended to deviate by ~+12 to +14 mmHg systolic and ~-10 mmHg diastolic and YHE BP Doctor Fit read ~15 mmHg higher systolic with more measurement errors. The article highlights that Samsung received FDA clearance for blood-pressure tracking (with Amazfit clearance limited to outside the US unless the account is set accordingly) and frames the most accurate device choice for continuous home monitoring as a near-term positive for consumers.
This is more of a product-validation datapoint than a fundamental earnings driver. The near-term winner is Samsung’s wearable franchise: if health features are becoming a purchase filter, regulatory-cleared functionality can support premium pricing and reduce churn in the high-end Android cohort. That said, the monetization is indirect — the feature matters because it helps defend ecosystem lock-in, not because it adds meaningful standalone revenue today.
The bigger competitive signal is for Apple and Garmin. Apple’s watch narrative is increasingly judged against a moving benchmark of “medical-adjacent” functionality, so any delay in delivering reliable BP capability risks ceding the health moat to Android devices over the next 1-3 product cycles. Garmin’s risk is subtler: it is not losing core endurance users, but it can get boxed into a pure fitness/battery narrative if health-monitoring breadth keeps expanding; that can pressure multiple expansion even if units stay resilient.
The contrarian view is that this category may be overhyped from a market-cap perspective. BP monitoring still requires calibration, has liability and accuracy constraints, and is unlikely to become a mass-replacement for cuffs without broader clinical validation. If the consumer takeaway is that “the best device is the one that is easiest and most accurate,” the market may actually reward the most regulated and vertically integrated players, but the total revenue pool remains small unless insurers/providers embrace it.
Catalysts are mostly 1-3 months: new watch launches, software updates, and any FDA/regional clearance announcements. The thesis breaks if Apple ships a credible real-time BP solution or if Samsung’s implementation remains too inconsistent for mainstream adoption. Over 6-18 months, the key question is whether BP becomes a table-stakes health feature that supports premium ASPs, or a niche function that never moves the needle beyond marketing.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
